MediPharm Labs Corp (OTCPK:MEDIF)

Q1 2026 Medipharm Labs Corp Earnings Call Transcript

May 13, 2026 / 02:00 PM GMT

Release Date Price: $0.06346 (+1.05%)

Transcript

Key Points

Positve

MediPharm Labs Corp (MEDIF) returned to positive adjusted EBITDA in Q1 2026, demonstrating improved margin quality and lower operating expenses.
The company holds a unique combination of licenses, including Health Canada drug establishment license and EU GMP certification, which differentiates it in regulated medical and pharmaceutical channels.
MediPharm Labs Corp (MEDIF) is expanding its international medical cannabis market, with successful shipments to France and New Zealand, and continued growth in Germany.
The company maintains a strong balance sheet with $9.9 million in cash and virtually no debt, allowing flexibility for strategic opportunities.
Gross profit margin was 37%, among the higher levels achieved by the company, reflecting disciplined product mix management and cost control.

Negative

Revenue decreased to $9.0 million from $10.8 million in Q1 2025, reflecting typical first-quarter seasonality and market adjustments.
The Canadian medical cannabis revenue remained flat at $3.0 million, indicating challenges in domestic market growth.
The company faces near-term headwinds due to Veteran Affairs Canada's reimbursement changes, which could impact margins.
Net loss for the quarter was $0.9 million, compared to $0.4 million in the prior-year period, partly due to the absence of break fee income.
The U.S. Schedule III rescheduling of medical cannabis presents long-term opportunities but does not provide immediate P&L impact for MediPharm Labs Corp (MEDIF).

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LABS.TO - Medipharm Labs Corp
Q1 2026 Medipharm Labs Corp Earnings Call
May 13, 2026 / 02:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you for standing by and welcome to the Mediform Labs conference call to discuss the company's 2026 Q1 results.

Our speaker on today's call is Greg Hunter, Interim's CEO and Chief Financial Officer.

As a reminder, all participants are in a listen-only mode and the conference is being recorded.

After management's presentation, we will take questions from the analyst community on the telephone and then take written questions through the Q&A feature on the webcast.

The information during this call should be considered together with the more detailed information, disclosure, financial data, and statements available on the company's website and in the Setter Plus profile at setterplus.ca.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.